Euflexxa (1% Sodium Hyaluronate)
FDA premarket approval P010029/S029 · decided 2020-01-02
Approval details
- PMA number
- P010029
- Supplement
- S029
- Supplement type
- 30-Day Notice
- Supplement reason
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
- Trade name
- Euflexxa (1% Sodium Hyaluronate)
- Generic name
- Acid, hyaluronic, intraarticular
- Applicant
- Ferring Pharmaceuticals, Inc.
- Date received
- 2019-12-09
- Decision date
- 2020-01-02
- Days to decision
- 24 days
- Decision code
- OK30
- Product code
- MOZ
- Advisory committee
- Orthopedic
- Expedited review
- No
- Location
- Parsippany, NJ
- Statement
- Elimination of syringeability testing from finished product testing, and the elimination of the syringeability test parameter from EUFLEXXA release and stability test parameters.
Class III intelligence, same tools
PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.